drugset / Trial / NCT07490119
Becotatug Vedotin Combined With Cetuximab in the Later-line Treatment of Metastatic RAS Wild-type Colorectal Cancer
NaSingle-groupOpen-labelTreatment
Summary
This is a single-arm, single-center, exploratory study aimed at exploring the treatment of RAS wild-type recurrent/metastatic colorectal cancer with the combination of becotatug vedotin and cetuximab as a salvage therapy
Timeline
- Start
- 2026-06-01
- Primary completion
- 2028-06-01
- Completion
- 2029-06-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Becotatug Vedotin | Monoclonal antibody | 2 mg/kg | Intravenous |
| Subject | Cetuximab | Monoclonal antibody | 500 mg/m2 | Intravenous |